Search research articles
Contact Us
Filters
Showing results (41-50 of 59) with videos related to
Page
of 6
Sort By:
The Journal of Clinical Psychiatry
|
January 7, 2015
Efficacy and safety of low- and high-dose cariprazine in acute and mixed mania associated with bipolar I disorder: a double-blind, placebo-controlled study
Joseph R Calabrese, Paul E Keck, Anju Starace, et al.
BMC Psychiatry
|
August 25, 2017
The safety and tolerability of cariprazine in long-term treatment of schizophrenia: a post hoc pooled analysis
Henry A Nasrallah, Willie Earley, Andrew J Cutler, et al.
The Journal of Clinical Psychiatry
|
December 31, 2015
Cariprazine in acute exacerbation of schizophrenia: a fixed-dose, phase 3, randomized, double-blind, placebo- and active-controlled trial
Suresh Durgam, Andrew J Cutler, Kaifeng Lu, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
|
January 14, 2023
The efficacy of lumateperone on symptoms of depression in bipolar I and bipolar II disorder: Secondary and post hoc analyses
Roger S McIntyre, Suresh Durgam, Susan G Kozauer, et al.
Journal of Affective Disorders
|
December 23, 2014
Cariprazine in the treatment of acute mania in bipolar I disorder: a double-blind, placebo-controlled, phase III trial
Gary S Sachs, William M Greenberg, Anju Starace, et al.
International Clinical Psychopharmacology
|
September 20, 2016
Effects of vilazodone on sexual functioning in healthy adults: results from a randomized, double-blind, placebo-controlled, and active-controlled study
Anita H Clayton, Suresh Durgam, Dayong Li, et al.
International Clinical Psychopharmacology
|
December 12, 2018
Long-term safety and tolerability of cariprazine as adjunctive therapy in major depressive disorder
Eduard Vieta, Willie R Earley, Maria V Burgess, et al.
Schizophrenia Research
|
July 19, 2016
Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled trial
Suresh Durgam, Willie Earley, Rui Li, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
|
November 25, 2018
Efficacy of cariprazine across symptom domains in patients with acute exacerbation of schizophrenia: Pooled analyses from 3 phase II/III studies
Stephen Marder, W Wolfgang Fleischhacker, Willie Earley, et al.
Journal of Clinical Psychopharmacology
|
February 13, 2025
Lumateperone for the Treatment of Major Depressive Disorder With Mixed Features or Bipolar Depression With Mixed Features: A Randomized Placebo-Controlled Trial
Suresh Durgam, Susan G Kozauer, Willie R Earley, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 59) with videos related to
Sort By:
Page
of 6
The Journal of Clinical Psychiatry
|
January 7, 2015
Efficacy and safety of low- and high-dose cariprazine in acute and mixed mania associated with bipolar I disorder: a double-blind, placebo-controlled study
Joseph R Calabrese, Paul E Keck, Anju Starace, et al.
BMC Psychiatry
|
August 25, 2017
The safety and tolerability of cariprazine in long-term treatment of schizophrenia: a post hoc pooled analysis
Henry A Nasrallah, Willie Earley, Andrew J Cutler, et al.
The Journal of Clinical Psychiatry
|
December 31, 2015
Cariprazine in acute exacerbation of schizophrenia: a fixed-dose, phase 3, randomized, double-blind, placebo- and active-controlled trial
Suresh Durgam, Andrew J Cutler, Kaifeng Lu, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
|
January 14, 2023
The efficacy of lumateperone on symptoms of depression in bipolar I and bipolar II disorder: Secondary and post hoc analyses
Roger S McIntyre, Suresh Durgam, Susan G Kozauer, et al.
Journal of Affective Disorders
|
December 23, 2014
Cariprazine in the treatment of acute mania in bipolar I disorder: a double-blind, placebo-controlled, phase III trial
Gary S Sachs, William M Greenberg, Anju Starace, et al.
International Clinical Psychopharmacology
|
September 20, 2016
Effects of vilazodone on sexual functioning in healthy adults: results from a randomized, double-blind, placebo-controlled, and active-controlled study
Anita H Clayton, Suresh Durgam, Dayong Li, et al.
International Clinical Psychopharmacology
|
December 12, 2018
Long-term safety and tolerability of cariprazine as adjunctive therapy in major depressive disorder
Eduard Vieta, Willie R Earley, Maria V Burgess, et al.
Schizophrenia Research
|
July 19, 2016
Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled trial
Suresh Durgam, Willie Earley, Rui Li, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
|
November 25, 2018
Efficacy of cariprazine across symptom domains in patients with acute exacerbation of schizophrenia: Pooled analyses from 3 phase II/III studies
Stephen Marder, W Wolfgang Fleischhacker, Willie Earley, et al.
Journal of Clinical Psychopharmacology
|
February 13, 2025
Lumateperone for the Treatment of Major Depressive Disorder With Mixed Features or Bipolar Depression With Mixed Features: A Randomized Placebo-Controlled Trial
Suresh Durgam, Susan G Kozauer, Willie R Earley, et al.
Page
of 6